ReviewPharmacotherapy2007
Pharmacogenetics of beta-blockers.
Review in Pharmacotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 155 citations in OpenAlex.
- Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2023Pooled it
- Pharmacogenetic and microRNA mechanisms of beta blocker use on bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Trial
- Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?Circulation. Cardiovascular genetics · 2014Trial
- beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.Clinical pharmacology and therapeutics · 2008Trial
- CYP2D6 as an Emerging Endogenous Oxidative Stress Modulator in Cardiovascular Disease: Genetic, Pharmacological, and Redox Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.NPJ genomic medicine · 2025Review
- Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- β1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome.Future science OA · 2023Article
- Associations between SelectedMedicina (Kaunas, Lithuania) · 2023Article
- Genetic heterogeneity in cardiovascular disease across ancestries: Insights for mechanisms and therapeutic intervention.Cambridge prisms. Precision medicine · 2023Review
- Screening and validation of double allele-specific binding F-primers for the measurement of antihypertensive pharmacogenomics.Frontiers in medicine · 2023Article
- Article
- Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2022Review
- Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?Journal of personalized medicine · 2021Review
- Pharmacogenomic Effects of β-Blocker Use on Femoral Neck Bone Mineral Density.Journal of the Endocrine Society · 2021Article
- Pharmacotherapy of atrial fibrillation in COVID-19 patients.Cardiology journal · 2021Article
- Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.Circulation. Heart failure · 2020Article
- COVID-19: Implications for People with Chagas Disease.Global heart · 2020Review
- Pharmacogenetic factors affecting β-blocker metabolism and response.Expert opinion on drug metabolism & toxicology · 2020Review
- Bisoprolol responses (PK/PD) in hypertensive patients: A cytochrome P450 (CYP) 2D6 targeted polymorphism study.Saudi journal of biological sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Beta-blockers are an important cardiovascular drug class, recommended as first-line treatment of numerous diseases such as heart failure, hypertension, and angina, as well as treatment after myocardial infarction. However, responses to a beta-blocker are variable among patients. Results of numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to beta-blockers. This review summarizes the pharmacogenetic data for beta-blockers in patients with various diseases and discusses the potential implications of beta-blocker pharmacogenetics in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.